The Philadelphia host committee of the Democratic National Convention has hired a healthcare agency to manage its social media and digital this week--and …

So far, the group of newly approved multiple myeloma meds hasn’t proved much of a threat to older, more established therapies. But that could all change soon.

Rebel Depomed investor Starboard Value wants a special meeting as soon as possible--and to get its wish, it’s taking matters into its own hands.

In its second Opdivo tie-up in as many days, Bristol-Myers Squibb has teamed up with Johnson & Johnson to test its drug in yet another variety of lung…

Earlier this month, Stada proposed a slate of four new directors--but now, as promised, its rebel shareholder is out with an alternative lineup.

Celgene’s best-selling drug Revlimid fell short in a lymphoma trial, putting its hopes for a $1 billion revenue boost in danger.

Eli Lilly isn’t expecting an easy drug pricing environment going forward. But never fear, investors: It’s expecting volume gains.

Amid intense hep C competition, Gilead reported plummeting Q2 sales for the megablockbuster franchise and slashed its full-year revenue forecast, putting more…

On Monday, the New Jersey pharma announced its rVSV-ZEBOV has won the FDA’s Breakthrough Therapy Designation and the EMA’s Priority Medicines status.